Oculis Holding AG (NASDAQ:OCS) Receives $38.00 Consensus Target Price from Brokerages

Oculis Holding AG (NASDAQ:OCS) has been given an average recommendation of “Moderate Buy” by the ten analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $38.00.

OCS has been the topic of several analyst reports. Wall Street Zen raised Oculis from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Guggenheim reduced their price objective on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a report on Friday, July 17th. Stifel Nicolaus dropped their target price on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, June 1st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Oculis in a report on Tuesday, August 25th.

Hedge Funds Weigh In On Oculis

Several hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. raised its stake in Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares in the last quarter. Koshinski Asset Management Inc. bought a new position in shares of Oculis in the first quarter worth about $238,000. Millennium Management LLC acquired a new stake in shares of Oculis in the 4th quarter valued at approximately $312,000. Marshall Wace LLP acquired a new stake in shares of Oculis in the 2nd quarter valued at approximately $393,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Oculis during the fourth quarter worth $499,000. Institutional investors own 22.30% of the company’s stock.

Oculis Price Performance

Shares of OCS opened at $12.21 on Monday. Oculis has a 12 month low of $10.52 and a 12 month high of $34.47. The firm’s 50 day moving average is $12.56 and its 200-day moving average is $20.74. The stock has a market capitalization of $707.98 million, a PE ratio of -7.02 and a beta of 0.51. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.20) earnings per share (EPS) for the quarter. The company had revenue of $0.38 million during the quarter. Oculis had a negative net margin of 6,777.18% and a negative return on equity of 42.61%. Equities research analysts forecast that Oculis will post -2.01 EPS for the current year.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.